Zai Lab reaffirms $560M-$590M 2025 revenue target as VYVGART and pipeline drive growth
Source: SeekingAlpha
2025-08-07 22:30:11 ET
More on Zai Lab
- Zai Lab Limited (ZLAB) Q2 2025 Earnings Call Transcript
- Zai Lab Limited Is Well Positioned For Long-Term Growth
- Zai Lab Limited: Banking On Chinese Pharma Growth
- Zai Lab Q2 2025 Earnings Preview
- Amgen, Zai Lab succeed in gastric cancer study
Read the full article on Seeking Alpha
For further details see:
Zai Lab reaffirms $560M-$590M 2025 revenue target as VYVGART and pipeline drive growth
Zai Lab Limited
NASDAQ: ZLAB
ZLAB Trading
-2.23% G/L:
$19.08 Last:
148,553 Volume:
$19.22 Open:
ZLAB Latest News
February 26, 2026 07:00:00 am
Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
ZLAB Stock Data
$2,174,273,322
105,108,310
0.9%
39
N/A
Biotechnology & Life Sciences
Healthcare
CN
Shanghai
